NanoViricides Inc (NNVC) News

Form 8-K - Current report

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Form DEF 14A - Other definitive proxy statements

Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]

Form 8-K - Current report

Form 424B5 - Prospectus [Rule 424(b)(5)]

NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon

  SHELTON, CT -- May 2, 2024 -- InvestorsHub NewsWire -- NanoViricides, Inc. (NYSE Amer: NNVC) (the "Company"), a...

Form 8-K - Current report

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Form 8-K - Current report

Form DEF 14A - Other definitive proxy statements

Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]

Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405

Form 8-K - Current report

Clinical Trial of Broad-Spectrum Antiviral Drug NV-CoV-2 is Progressing Well, Says NanoViricides - NV-CoV-2 is Positioned to Fulfill Many Unmet Medical Needs

SHELTON, CO -- July 6, 2023 -- InvestorsHub NewsWire -- NanoViricides, Inc. (NYSE American:NNVC) (the "Company") reports that the...